Angion to Participate in Upcoming September Investment Conferences

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Details are as follows:

Event: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13th Time: 7:00am Eastern US Daylight Time

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date: Wednesday, September 22nd Time: 10:45am Eastern US Daylight Time

Webcasts of the presentation and fireside chat will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcasts of both events will remain archived on Angion’s website for approximately 30 days.

About AngionAngion is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluated in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation and a Phase 2 trial in cardiac-surgery associated acute kidney injury. Angion is scheduled to begin a Phase 2 trial evaluating ANG-3070, an oral tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in patients with primary proteinuric kidney diseases. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.

Contact
Daniel Ferry
LifeSci Advisors
617-430-7576
[email protected]

You May Also Be Interested In

• Channelscaler Brings AI-Powered Partner Relationship Management to Microsoft Marketplace
• BillingPlatform Expands Executive Team with Three Industry Veterans to Accelerate AI-Native Platform Strategy and Scale its Market Advantage
• In HelloNation, Security Expert Corey Wild Explains What Makes Patrol Services Effective